Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Emerging research is evaluating whether GLP-1 medications may affect kidney-related outcomes in people with type 2 diabetes These medications are FDA-approved for blood sugar control and chronic weight management, and some studies have explored potential secondary effects on blood pressure and inflammation Reported risks include dehydration and low blood pressure, particularly early in treatment Individuals using GLP-1 medications should work with their provider to monitor kidney function and stay properly hydrated GLP-1 receptor agonistssuch as semaglutide, the active ingredient in FDA-approved medications like Ozempic and Wegovyare widely prescribed for type 2 diabetes and chronic weight management
The Journal of biological chemistry , 267 (29), 2054720550
But in the subgroup prescribed a GLP-1RA, the rate of antidepressant prescriptions was much higher 34 percent
What medication is Wegovy
